Benefits
Supports Energy Metabolism
Niacin is a precursor to coenzymes NAD (nicotinamide adenine dinucleotide) and NADP, which are critical for metabolizing carbohydrates, fats, and proteins into energy, supporting cellular functions.
Improves Lipid Profiles
Nicotinic acid can lower LDL ("bad") cholesterol, raise HDL ("good") cholesterol, and reduce triglycerides, potentially reducing the risk of cardiovascular disease when used under medical supervision.
Supports Skin Health
Niacin helps maintain healthy skin by supporting cell repair and barrier function, and it may reduce symptoms of certain skin conditions like pellagra (caused by niacin deficiency).
Promotes Nervous System Function
NAD is vital for nerve signaling and brain health, potentially supporting cognitive function and protecting against neurodegenerative conditions.
Aids DNA Repair and Cell Health
Niacin-dependent enzymes (via NAD) are involved in DNA repair and gene stability, which may reduce cellular damage and support overall health.
May Improve Blood Sugar Control
Niacin may enhance insulin sensitivity in some cases, though high doses can sometimes impair glucose tolerance, requiring medical oversight.
Mechanism of action
Coenzyme Formation
Niacin is converted into nicotinamide adenine dinucleotide (NAD) and NADP, coenzymes critical for over 400 enzymatic reactions. These coenzymes act as electron carriers in redox reactions.
Energy Metabolism
NAD is vital for glycolysis, the citric acid cycle, and oxidative phosphorylation, facilitating the breakdown of carbohydrates, fats, and proteins to produce ATP, the cell’s energy currency. NADP supports biosynthetic pathways, such as fatty acid and cholesterol synthesis.
Lipid Regulation (Nicotinic Acid Form)
Nicotinic acid binds to the G protein-coupled receptor GPR109A in adipocytes, reducing cyclic AMP levels, which inhibits lipolysis. This decreases free fatty acid release, lowering LDL cholesterol and triglycerides while increasing HDL cholesterol. It also reduces hepatic VLDL production, further improving lipid profiles.
DNA Repair and Cell Maintenance
NAD is a substrate for enzymes like PARP (poly ADP-ribose polymerase), which repairs DNA damage, and sirtuins, which regulate gene expression and cellular aging, supporting cell health.
Neurological and Skin Health
NAD supports nerve signaling and myelin synthesis, while its role in cellular repair promotes healthy skin and mucosal tissues.
Clinical trials
Clinical trial conducted 1966-1975 involving 8,341 men aged 30-64 with prior myocardial infarction receiving niacin (3 g/day) vs placebo for 5 years, with mortality follow-up to 15 years. (Coronary Drug Project Research Group;, J Am Coll Cardiol — long-term follow-up)
8,341 men with prior MI.
Niacin reduced recurrent MI during the 5-year trial. After ~9 years post-trial, niacin group showed ~11% reduction in all-cause mortality vs placebo (a delayed mortality benefit). Historical context: this was a foundational trial supporting niacin's CV benefits. However, CDP was conducted before statins existed — the modern question is whether niacin adds CV benefit to statin therapy, which was the focus of AIM-HIGH and HPS2-THRIVE (both negative).
Clinical trial (2005-2011) in 3,414 patients with stable atherosclerotic CVD, low HDL, and high triglycerides receiving extended-release niacin + statin vs statin alone. (AIM-HIGH, NEJM)
3,414 statin-treated CVD patients.
Primary endpoint negative: niacin + statin did not reduce CV events vs statin alone. Trial stopped early for futility. Modest signal for ischemic stroke increase in niacin arm. This major negative trial substantially deflated enthusiasm for adding niacin to statin therapy.
Large clinical trial (2007-2014) in 25,673 high-risk patients with prior vascular disease receiving extended-release niacin + laropiprant + statin vs statin alone. (HPS2-THRIVE Collaborative, NEJM)
25,673 high-risk vascular disease patients.
Primary endpoint negative: niacin + laropiprant did not reduce major vascular events vs placebo. Critical harm signals: increased serious adverse events including diabetes (newly diagnosed +55% RR), bleeding, infections. Combined with AIM-HIGH, these two large trials effectively ended routine niacin use as add-on to statins. Modern lipid management uses statins + ezetimibe + PCSK9 inhibitors (alirocumab, evolocumab) + bempedoic acid.
Preclinical study by Indiana University School of Medicine investigating niacin's effects on AD pathology in animal models. (2022)
Animal models — not clinical trial.
Niacin showed potential effects on amyloid clearance and neuroinflammation in animal models. Critical caveat: this is preclinical data; does not establish human clinical efficacy. Many AD targets that look promising in animal models have failed translation to humans. Citation caveat: original citation was press release, not peer-reviewed publication; verify primary literature.
Population-based cohort study (2003-2018) in 26,746 US adults from NHANES examining association between dietary niacin intake and mortality.
26,746 US adults. Cohort.
Higher dietary niacin intake associated with lower all-cause mortality. Critical caveat: observational — cannot establish causation; higher niacin intake correlates with overall better dietary patterns. Does not support high-dose niacin supplementation.